1. Home
  2. KOP vs TRVI Comparison

KOP vs TRVI Comparison

Compare KOP & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOP
  • TRVI
  • Stock Information
  • Founded
  • KOP 1988
  • TRVI 2011
  • Country
  • KOP United States
  • TRVI United States
  • Employees
  • KOP N/A
  • TRVI N/A
  • Industry
  • KOP Forest Products
  • TRVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • KOP Basic Materials
  • TRVI Health Care
  • Exchange
  • KOP Nasdaq
  • TRVI Nasdaq
  • Market Cap
  • KOP 680.9M
  • TRVI 725.7M
  • IPO Year
  • KOP 2006
  • TRVI 2019
  • Fundamental
  • Price
  • KOP $28.88
  • TRVI $7.01
  • Analyst Decision
  • KOP Strong Buy
  • TRVI Strong Buy
  • Analyst Count
  • KOP 2
  • TRVI 10
  • Target Price
  • KOP $52.50
  • TRVI $19.35
  • AVG Volume (30 Days)
  • KOP 189.1K
  • TRVI 2.0M
  • Earning Date
  • KOP 08-08-2025
  • TRVI 11-05-2025
  • Dividend Yield
  • KOP 1.11%
  • TRVI N/A
  • EPS Growth
  • KOP N/A
  • TRVI N/A
  • EPS
  • KOP 0.73
  • TRVI N/A
  • Revenue
  • KOP $1,992,600,000.00
  • TRVI N/A
  • Revenue This Year
  • KOP N/A
  • TRVI N/A
  • Revenue Next Year
  • KOP $1.74
  • TRVI N/A
  • P/E Ratio
  • KOP $39.50
  • TRVI N/A
  • Revenue Growth
  • KOP N/A
  • TRVI N/A
  • 52 Week Low
  • KOP $22.99
  • TRVI $2.36
  • 52 Week High
  • KOP $39.83
  • TRVI $8.78
  • Technical
  • Relative Strength Index (RSI)
  • KOP 42.38
  • TRVI 44.05
  • Support Level
  • KOP $27.24
  • TRVI $7.09
  • Resistance Level
  • KOP $28.98
  • TRVI $8.78
  • Average True Range (ATR)
  • KOP 0.87
  • TRVI 0.43
  • MACD
  • KOP -0.00
  • TRVI -0.07
  • Stochastic Oscillator
  • KOP 50.77
  • TRVI 4.32

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: